Pioneering U.S. Medication Safety
Seegnal Initiates First U.S. Pilot Program to Reduce Elder Medication Errors
Seegnal Inc. (TSXV: SEGN) has kicked off its first U.S. pilot program, partnering with a U.K.-based long-term care provider to tackle one of geriatric medicine's most dangerous problems: medication harm in elderly patients. The company confirmed on June 19, 2026 that it received patient data, starting an 8-to-12-week evaluation clock that could extend into a longer commercial contract, according to GlobeNewswire.
The stakes are significant. An estimated 99,628 emergency hospitalizations happen every year in U.S. adults aged 65 and older because of adverse drug events. Seegnal's platform, already used by more than 15,000 clinicians daily, is designed to help doctors prescribe more precisely — and catch dangerous drug combinations before they cause harm, Fort McMurray Today reported.
From LOI to Live Pilot in Under Six Weeks
The path to this pilot moved fast. Seegnal signed a formal Letter of Intent with the unnamed long-term care provider on May 5, 2026. The company announced that deal publicly on May 19. Less than a month later, on June 5, Seegnal was accepted into the AgeTech Collaborative™ from AARP Accelerator Program — giving it a strategic foothold in the U.S. aging-tech market. Data receipt was confirmed on June 19, officially starting the pilot, according to GlobeNewswire.
The pilot partner's identity remains protected under a confidentiality agreement. What is known is that the provider is U.K.-based but operates significantly in U.S. long-term care — a setup that mirrors Seegnal's existing international footprint, which includes work at Tel Aviv's Sourasky Medical Center.
How Seegnal's Platform Cuts Through Alert Fatigue
Most clinical decision support tools flood doctors with warnings. Studies show physicians ignore up to 90% of alerts because the warnings are too generic. Seegnal takes a different approach. Its platform — which the company calls a "Prescription Operating System" — generates personalized, explainable recommendations. The result: a reported 94% reduction in alert volume compared to legacy systems, according to internal use-case data cited by Edmonton Sun.
The platform runs as a SaaS product, meaning it plugs directly into a facility's existing Electronic Medical Records system. No hardware overhaul is needed. That matters in long-term care, where budgets are tight and IT resources are limited. The system acts as an "intelligence layer" that supports — rather than replaces — clinical judgment.
AARP Accelerator Adds Credibility and U.S. Market Access
Seegnal's June 5 acceptance into the AgeTech Collaborative™ from AARP is more than a badge. The program connects the company to a network of over 100 enterprise partners and real-world testbed sites across the U.S. AARP leadership said Seegnal was chosen because its platform directly addresses the "polypharmacy crisis" — a term for the dangers of elderly patients taking multiple medications at once — facing the 1.2 million Americans living in nursing facilities, Woodstock Sentinel Review reported.
Polypharmacy is a growing problem. Older adults are often prescribed five or more drugs at once. Dangerous interactions can cause falls, confusion, and kidney failure. Prior large-scale trials of Seegnal's technology showed a 5.6% reduction in hospitalizations, according to data published in the American Journal of Pharmacy Benefits.
A Successful Pilot Could Unlock a Much Bigger U.S. Push
If the 8-to-12-week pilot goes well, Seegnal expects an extended evaluation period — a step that typically precedes a multi-year enterprise contract. CEO Elad Bibi-Aviv has described the U.S. long-term care market as the "converging point" for polypharmacy risks and clinical complexity. The company sees this pilot as the first step toward expanding into U.S. hospitals and outpatient settings, Prince George Post reported.
The financial upside is clear. By targeting 99,628 preventable hospitalizations per year, Seegnal is positioning itself to capture a share of billions in avoidable healthcare spending. Success in this pilot would also lift the company's profile on the TSX Venture Exchange, where it trades under the ticker SEGN, according to Whitecourt Star.
Sentiment
NeutralPublishers
5
Articles
5
Reach
5
